Brian Cheng
Stock Analyst at JP Morgan
(2.25)
# 2,812
Out of 5,090 analysts
73
Total ratings
46.55%
Success rate
-2.61%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPK OPKO Health | Initiates: Neutral | n/a | $1.35 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $87.54 | -7.47% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $9.77 | -48.80% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $18.05 | -0.28% | 5 | Nov 6, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $71 → $82 | $78.51 | +4.45% | 1 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $26.43 | -12.98% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.45 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.30 | - | 1 | Oct 10, 2025 | |
| ABSI Absci | Initiates: Overweight | n/a | $3.68 | - | 1 | Oct 2, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $37 → $33 | $22.94 | +43.85% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $44.95 | +4.56% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $21.18 | -5.55% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $58.85 | +18.95% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.76 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $20.12 | +9.34% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $30.68 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.44 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $7.88 | +318.78% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.80 | +234.26% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $27.42 | +355.87% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.85 | +1,540.69% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.54 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.56 | +962.51% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.22 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.38 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $6.78 | +1,153.69% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.86 | +167.35% | 1 | Aug 3, 2021 |
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $87.54
Upside: -7.47%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $9.77
Upside: -48.80%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $18.05
Upside: -0.28%
Revolution Medicines
Nov 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $78.51
Upside: +4.45%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $26.43
Upside: -12.98%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.45
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.30
Upside: -
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.68
Upside: -
Immunovant
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $22.94
Upside: +43.85%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $44.95
Upside: +4.56%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $21.18
Upside: -5.55%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $58.85
Upside: +18.95%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.76
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $20.12
Upside: +9.34%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $30.68
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.44
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $7.88
Upside: +318.78%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.80
Upside: +234.26%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $27.42
Upside: +355.87%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.85
Upside: +1,540.69%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.54
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.56
Upside: +962.51%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.22
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $3.38
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $6.78
Upside: +1,153.69%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.86
Upside: +167.35%